Direct-acting antivirals

Intervention

4 papers study it5 findings

Across all fields, 4 papers: 3 observational studies in people, 1 in animals

  • 3 independent labs in 3 countries
  • Funders: Centro de Investigación Biomédica en Red de Cáncer and others
  • Humans3
  • Animals1

Outcomes

4

Telomere length

no changein humans1

1 study
  1. Direct-acting antivirals have no effect on telomere length in humans.

    “No significant differences in telomere shortening were observed between groups.”

    Humans48 weeksn = 70

    Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Telomere length

Senescence-associated secretory phenotype (SASP)

downin humans1

1 study
  1. Direct-acting antivirals decrease senescence-associated secretory phenotype (SASP) in humans.

    “Overall, the CHC group reduced the levels of oxidative stress and SASP markers to levels like those of the HIV group.”

    Humansin PLWHIV with active HCV-chronic infection48 weeksn = 23

    Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Senescence-associated secretory phenotype (SASP)

Oxidative stress and ROS signaling

downin humans1

1 study
  1. Direct-acting antivirals decrease oxidative stress and ROS signaling in humans.

    “Overall, the CHC group reduced the levels of oxidative stress and SASP markers to levels like those of the HIV group.”

    Humansin PLWHIV with active HCV-chronic infection48 weeksn = 23

    Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Oxidative stress and ROS signaling

Epigenetic age

downin humans1

1 study
  1. Direct-acting antivirals decrease epigenetic age in humans (decreased to 1.37 years, p = 0.01).

    “Accordingly, EAA decreased to 1.37 years at long-term follow-up. The decrease in EAA was significant only between the end of treatment and follow-up (p = 0.01).”

    Human trialbetween end of treatment and long-term follow-up (median 96 weeks)peripheral blood mononuclear cellsn = 54

    Reverse inflammaging: Long-term effects of HCV cure on biological age

    Journal of hepatology

More on Epigenetic age

Associations

1

DPP4

downin humans1

1 study
  1. Direct-acting antivirals are associated with DPP4 in humans.

    “DPP4 protein levels decreased with viral clearance”

    Humanshepatitis C infection with dysglycemia

    Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression

    JCI insight

More on DPP4

Latest